Recombinant Oncolytic Vaccinia Virus

重组溶瘤痘苗病毒

Report date: 2022/04/11 15:49:01

Base Information

Drug NameRecombinant Oncolytic Vaccinia Virus
Drug Alias Name重组溶瘤痘苗病毒注射液T601TG-6002T-601
ClassificationCell and gene therapy > Gene therapyBiologics > Oncolytic virus
Mechanisms of ActionDNA synthesis inhibitorsGene transferenceThymidylate synthase inhibitors
TargetsThymidylate synthase
Therapy Area/IndicationsSolid tumoursBrain NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomFranceMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTasly Chuangshijie (Tianjin) Biopharmaceutical Co LtdTransgene Sa
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTasly Chuangshijie (Tianjin) Biopharmaceutical Co Ltd
Inactive CompaniesTransgene Sa
Active IndicationsGastrointestinal Neoplasms
Inactive IndicationsSolid tumoursBrain NeoplasmsColorectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A